Dow Jones 30 Stocks SEC Filings — July 15, 2026
The seven filings from Dow 30 constituents reveal a mixed picture for the second quarter of 2026. Johnson & Johnson delivered solid top-line growth of 6.6% YoY, driven by its Innovative Medicine and MedTech segments, and raised its full-year guidance, signaling confidence. However, GAAP earnings were flat, and currency headwinds and a major drug's patent cliff (STELARA) pose ongoing risks. Nike's annual report shows a company in a prolonged downturn, with flat revenues and a 10% decline from fiscal 2024, alongside significant weakness in Greater China (-11%) and its Converse brand (-31%), though its EBIT margin showed a slight improvement. American Express's delinquency data is a mixed signal: improving net write-off rates are partly due to a one-time sale of bad debt, masking underlying consumer credit trends. The remaining filings are low materiality, covering routine governance updates (Visa), proxy solicitations (Nike), and a minor insider transaction (Microsoft). The overarching theme is a bifurcation between healthcare strength and consumer-facing headwinds, with credit quality requiring close monitoring.